{
  "id": 9166942,
  "title": "Imaging agent may improve diagnoses for rare heart disease",
  "url": "https://urgent.news/2026/09/22/imaging-agent-may-improve-diagnoses-for-rare-heart-disease",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-22T17:00:04.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-imaging-agent-rare-heart-disease.html"
  },
  "original_language": "en",
  "account": "A new radiotracer, iodine-124-evuzamitide, has shown promising results in diagnosing cardiac amyloidosis, a rare disease that causes abnormal protein buildup in the heart and leads to heart failure. The findings, published in JAMA, indicate that evuzamitide could be a valuable addition to diagnostic tools when standard imaging tests are inconclusive. In a phase III clinical trial involving 170 patients at 18 U.S. medical centers, evuzamitide demonstrated high sensitivity (94%) and specificity (86%) in diagnosing both transthyretin amyloidosis and immunoglobulin light chain amyloidosis. The radiotracer works by binding directly to amyloid fibrils, allowing for clearer diagnoses when standard imaging methods are ambiguous. However, further research is needed to determine the best way to integrate evuzamitide into clinical workflows.",
  "summary": "A PET/CT radiotracer demonstrated high sensitivity and specificity for diagnosing cardiac amyloidosis, a rare disease that causes abnormal protein buildup in the heart and heart failure, according to a recent clinical trial published in JAMA.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}